Beam Therapeutics Inc. - Common Stock - Nakit Akışı (NASDAQ:BEAM)

Financials

Genel Bakış Tablolar İstatistikler Temettüler

İşletme faaliyetlerinden elde edilen nakit -95.74 M-66.27 M22.53 M-149.19 M-347.25 M-345.1 M -369.73 M Yatırım faaliyetlerinden elde edilen nakit -100.12 M-294.14 M-461.34 M71.84 M185.01 M-121.44 M 28.92 M Finansman faaliyetlerinden elde edilen nakit 322.32 M756.14 M111.59 M276.45 M7.74 M478.05 M 101.28 M Serbest nakit akışı -95.74 M-66.27 M22.53 M-149.19 M-347.25 M-360.05 M -383.84 M

Beam Therapeutics Inc. - Common Stock

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.

BEAM

Financials

Beam Therapeutics Inc. - Common Stock

Haberler

Beam Therapeutics Inc. (BEAM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

These Are The Upcoming Catalysts For Crispr Therapeutics Stock (NASDAQ:CRSP)

H.C. Wainwright, Beam Therapeutics için al tavsiyesini yineledi

Beam Therapeutics Inc. (BEAM) Presents at ATS 2026 International Conference - Slideshow (NASDAQ:BEAM) 2026-05-20

Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?

Beam Therapeutics ATS’de AATD gen tedavisi verilerini sundu

H.C. Wainwright, Beam Therapeutics hissesi için al tavsiyesini korudu

Beam Therapeutics orak hücre tedavisi verilerini EHA’da sunacak

BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates

Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates

Three Best Genomics Stocks for Your Portfolio in 2026

Beam Therapeutics CMO’su Amy Simon 164.686 dolarlık hisse sattı